FDA Fires Neuralink Reviewers
Analysis based on 6 articles · First reported Feb 17, 2025 · Last updated Feb 19, 2025
The layoffs at the United States — Food and Drug Administration, particularly those affecting Neuralink reviewers, are expected to slow down the approval process for medical devices, potentially impacting the development timelines and market entry for companies like Neuralink. This event introduces regulatory uncertainty and could negatively affect investor confidence in the medical device sector, especially for companies reliant on timely FDA approvals.
The United States — Food and Drug Administration (FDA) has fired approximately 20 employees, including several who were reviewing applications for Elon Musk's brain implant company, Neuralink. These layoffs are part of a broader federal workforce purge led by Elon Musk, who spent over $250 billion to support Donald Trump's re-election and is now spearheading efforts to cut government spending. The affected employees were primarily probationary officers in the FDA's Office of Neurological and Physical Medicine Devices, responsible for overseeing clinical trial applications for brain-computer interface devices. While sources indicate the employees were not specifically targeted due to their work on Neuralink, the reduction in staff is expected to hamper the FDA's ability to quickly and safely process medical device applications, including those from Neuralink. Former FDA official Victor Krauthamer expressed concerns about the safety and protection of participants in Neuralink's trials due to these cuts. The White House stated that the Trump administration will abide by ethics laws, and both the FDA and Elon Musk have not yet commented on the matter. This situation raises questions about regulatory oversight and potential delays for innovative medical technologies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard